Specified Drug Use Survey on AJOVY Subcutaneous Injection for Long-term Use

Otsuka

Status: Enrolling

Conditions: Migraine Disorders

Treatments: Drug: Fremanezumab 225 Mg/1.5 mL Subcutaneous Solution

Study type: Observational

Funder types: Industry

Identifiers

NCT05342493

406-101-00013

Details and patient eligibility

About

To evaluate the long-term safety of AJOVY in patients under actual use conditions and to specifically evaluate cardiovascular events. In addition, information on efficacy will be collected.

Enrollment: 1,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Exclusion criteria

• patients with a known hypersensitivity to components of AJOVY

Trial design

1,000 participants in 1 patient group

Drug

Description:

Ajovy syringe for SC injection 225 mg.

Treatment:

Drug: Fremanezumab 225 Mg/1.5 mL Subcutaneous Solution